In silico drug screening applied to the melanoma-LC executable model revealed that mitogen-activated protein kinase (MAPK) pathway inhibitors such as dabrafenib and trametinib can prevent LC migration, despite effectively inhibiting melanoma cell growth, suggesting that care must be taken with the use of targeted therapies to treat primary tumors. Here, WNK2 is linked to melanoma.